The crosstalk between NF-κB and other pathways, such as ERK and AKT in HER2/EFGR signaling, leads to resistance to tyrosine kinase inhibitors in cancer cells IL6 via the NF-κB pathway link inflammatory responses to malignancy and generates an inflammatory feedback loop involved in trastuzumab resistance in HER2+ BC [74]. Here, ERBB2 is linked to breast cancer.